Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

This marks the first new class of medications for the brain disorder in several ... READ ON THE FOX NEWS APP STUDY REVEALS ...

Doctors sometimes use lithium to treat schizophrenia. However, it is not a primary treatment method and evidence of its ...

For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...

The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...

She added, "It works in a completely different way from any other currently used schizophrenia drugs. It has the potential to change the lives of millions of people." Cobenfy—its scientific name ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

According to the World Health Organization, schizophrenia affects roughly 24 million people worldwide, and is often difficult ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.